Baidu
map

Cancer Res:阴险!复旦科学家发现肿瘤能将杀伤性T细胞囚禁在淋巴结中,让调节T细胞成为“猪队友”

2018-10-29 奇点糕 奇点网

最近,复旦大学王宾教授领导的团队又发现,肿瘤将T细胞囚禁在了淋巴结中,使他们不能出去抗癌。不过,与上次不同的是,这次研究者们终于弄清了肿瘤的阴谋是如何得逞的,并且,他们还找到了解救T细胞的办法!

最近,复旦大学王宾教授领导的团队又发现,肿瘤将T细胞囚禁在了淋巴结中,使他们不能出去抗癌。不过,与上次不同的是,这次研究者们终于弄清了肿瘤的阴谋是如何得逞的,并且,他们还找到了解救T细胞的办法!

这个研究团队发现,肿瘤会“策反”机体的调节T细胞(Tregs),这种调节T细胞会在一种特殊的淋巴结中聚集,并将杀伤性T细胞(CD8+ T细胞)囚禁在这种淋巴结中。

更重要的是,他们还找到了调节T细胞囚禁杀伤性T细胞的时间窗口。这个窗口正是肿瘤发展的关键时期,在这个期间将杀伤性T细胞解救出来,会使肿瘤遭到沉重打击!这可能预示着一种高效率、低副作用的绝佳治癌策略,并推动免疫治疗的发展。这项研究发表在近期的著名学术期刊《癌症研究》上。


复旦大学王宾教授

这个被“策反”的调节T细胞平时主要参与调节自身的免疫系统,维持对自身抗原的耐受性,防止发生自身免疫性疾病。换句话说,调节T细胞能压制自身的免疫细胞。

但是,调节T细胞的这个特点却被肿瘤利用了。

早在2001年,科学家就发现调节T细胞会促进肿瘤的发展。而杀伤性T细胞与调节T细胞的比例还与患者生存期密切相关。这些证据都显示调节T细胞在肿瘤进程中扮演着重要角色,其作用可能是帮助肿瘤逃脱免疫系统的追杀。

然而,目前我们还不清楚调节T细胞为何会叛变,转而去协助肿瘤发展的。揭开其中的谜团对人类治疗癌症的具有重要意义。


调节T细胞是机体免疫系统的刹车

这次,王教授团队的研究终于为我们揭晓了答案,并找到了破解的办法!

这个研究是在小鼠中进行的。研究人员在给小鼠移植肿瘤后,发现小鼠的调节T细胞会在“肿瘤引流淋巴结(TDLNs)”中聚集(肿瘤引流淋巴结是指肿瘤细胞沿淋巴管能到达的淋巴结),无论是占比还是数量,都比其他淋巴结中要高。通过转录组测序也发现,肿瘤会诱使调节T细胞表达一些趋化因子,使肿瘤引流淋巴结的环境受调节T细“喜爱”,这可能是他们在这里中聚集的原因。

而淋巴是肿瘤转移的重要路径,同时也是机体防止肿瘤转移的阻击阵地。肿瘤引流淋巴结正是肿瘤免疫的关键节点,调节T细胞在肿瘤引流淋巴结中集结,并且还是由肿瘤引起的,说明事情并不简单。


肿瘤引流淋巴结是肿瘤免疫的重要战场

果然,研究人员将在这里聚集的调节T细胞分离出来进行分析,发现它们会表达更多的TGFβ1。而TGFβ1会抑制其他T细胞的活动,这表明调节T细胞的免疫压制能力变得更强了。

当他们将小鼠全身的调节T细胞消除后,发现小鼠身上的肿瘤接近被完全消灭了,与先前的结果一致。而更令人惊奇的是,通过局部诱导敲除的方法,只将肿瘤引流淋巴结里的调节T细胞消除,也达到了同样的效果。这表明调节T细胞在肿瘤引流淋巴结中的聚集,正是肿瘤发展的关键!

调节T细胞到底在肿瘤引流淋巴结干了什么,会推动肿瘤的发展呢?

考虑到调节T细胞的免疫抑制属性,研究人员分析它可能是影响了其他免疫细胞。于是,他们比较了消除调节T细胞前后,肿瘤引流淋巴结中免疫细胞的变化,果然发现了蹊跷。

在消除调节T细胞后,其他免疫细胞(如自然杀伤细胞,B细胞,巨噬细胞等)都没有变化,唯独杀伤性T细胞的数量有小幅增加,而且表达γ-干扰素的杀伤性T细胞数量明显增加了。与此同时,还发现没有调节T细胞后,杀伤性T细胞就能去杀伤肿瘤了。这说明杀伤性T细胞就是调节T细胞的目标!


消除肿瘤引流淋巴结里的调节T细胞后,杀伤性T细胞有明显变化,且肿瘤接近消失

接下来的问题是:调节T细胞到底对杀伤性T细胞做了什么?

通过实验,研究人员发现原来调节T细胞是限制了杀伤性T细胞的“人身”自由,不让他们从肿瘤引流淋巴结出去!而调节T细胞下手的部位正是杀伤性T细胞表面的S1P1受体,这个S1P1受体正是杀伤T细胞出入各个器官的“签证”。真相大白了,调节T细胞在肿瘤引流淋巴结中没收了杀伤T细胞的签证!

如果有读者看过我们上一篇关于脑部肿瘤将T细胞关在骨髓的文章,你可能还记得,那次肿瘤也是对S1P1动了手脚。

不过,与那次匪夷所思的事件不同的是,这次科学家们发现,调节T细胞与杀伤性T细胞发生了肢体冲突,两者在肿瘤引流淋巴中有直接的接触。

而肢体冲突的结果不仅是杀伤性T细胞被囚禁,其免疫活性也降低了,比如我们上面提到的γ-干扰素表达下降。此外,杀伤性T细胞的增殖也受到了影响,这也是消除调节T细胞后,杀伤性T细胞虽然能从肿瘤引流淋巴结出去,但淋巴结中的杀伤性T细胞数量却增加的原因。

杀伤性T细胞被囚禁了

现在,让我们总结一下,调节T细胞受肿瘤的“指使”,向肿瘤引流淋巴结集中,抑制杀伤性T细胞的增殖,抑制杀伤性T细胞的活性,还使杀伤性T细胞无法从肿瘤引流淋巴结中离开。

而这个事件发生在肿瘤移植后的第5-7天之间,在这个时间段内消除肿瘤引流淋巴结里的调节T细胞,会使肿瘤遭到重大打击!而错过了这个窗口再动手,就没有明显的效果了。


时间窗口很重要

这是科学家们首次发现调节T细胞能阻碍杀伤性T细胞S1P1受体的表达,将其困在肿瘤引流淋巴结中。而在一个特定的窗口,消除局部淋巴结里的调节T细胞能明显治疗癌症。

本文通讯作者王宾教授表示,这个研究可能有助于改善免疫治疗的效果。如果人体的杀伤性T细胞或者改造的CAR-T细胞被困于淋巴结中,则会影响免疫治疗的效率。若我们能通过消除局部调节T细胞的方法解救被困的T细胞,就有可能大幅提高免疫疗法的效果。

并且,相比于以往研究中消除全身的调节T细胞会引起严重副作用,局部消除的副作用则会轻得多。

完成本研究的实验团队正再接再厉,致力于开发可用于临床的消除局部调节T细胞的方法,这让我们充满期待!

当然,作者也表示,这只是在小鼠中的实验,在人类中是否有效还需要临床实验来验证,尤其是时间窗口的确定。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2019-10-25 秦至

    我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-30 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-30 saikp
  6. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-30 muzishouyi
  7. [GetPortalCommentsPageByObjectIdResponse(id=374367, encodeId=419e3e43679e, content=我家属免疫治疗后,腹膜后淋巴结肿大,但其他部位控制较好,也许是这个原因吧!很期待……, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a82314393, createdName=秦至, createdTime=Fri Oct 25 08:17:39 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696234, encodeId=9e6516962349a, content=<a href='/topic/show?id=d4a092049c8' target=_blank style='color:#2F92EE;'>#调节T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92049, encryptionId=d4a092049c8, topicName=调节T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5129877228, createdName=zhanfl, createdTime=Fri Feb 08 09:43:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802575, encodeId=c3b218025e504, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Mon Sep 09 06:43:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293049, encodeId=10ab1293049c4, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538545, encodeId=b82d153854544, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555289, encodeId=49ab15552891b, content=<a href='/topic/show?id=f367681e434' target=_blank style='color:#2F92EE;'>#猪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68174, encryptionId=f367681e434, topicName=猪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ec214601917, createdName=muzishouyi, createdTime=Tue Oct 30 22:43:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350841, encodeId=3da935084125, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 29 08:53:48 CST 2018, time=2018-10-29, status=1, ipAttribution=)]
    2018-10-29 ylzr123

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

相关资讯

Blood:树突细胞不能正常激活CD4 T细胞时可导致骨髓增生

中心点:骨髓增生可能是DC-CD4 T细胞相互作用缺陷以及DCs数目缺陷的结果。摘要:树突细胞(DCs)是适应性免疫应答起始的关键细胞。近期,有研究提示DCs具有抑制骨髓增殖的作用。在构成性敲除DCs的小鼠研究和由GATA2或IRF8突变引起DCs先天性缺陷的患者中均可观察到骨髓增生性疾病(MPD)。DC缺陷和MPD之间的机制关联尚不明确。目前流行的模型表明数目性树突细胞缺陷通过代偿性髓系分化导致

Cell Res:CD4lowHLA-G+ T细胞的消除能够克服前列腺癌治疗中的雄激素阻断抗性

雄激素阻断治疗(ADT )是前列腺癌(PCa)治疗的一种主要方法,但是在几乎所有的患者中,该疾病都能复发,并且产生雄激素阻断抗性。最近的数据表明了免疫细胞参与了雄激素阻断抗性前列腺癌(CRPC)的发展过程。特别的是,雄激素阻断后,T细胞在PCa患者和小鼠模型中均发生了扩展情况。然而,是否或者哪种T细胞亚型在CRPC的发展过程中具有重要作用仍旧未知。最近,有研究人员鉴定了一个新的CD4lowHLA-

Arthritis Rheumatol:先天淋巴样细胞和T细胞影响幼年特发性关节炎滑膜液中检测到的IL-17A特征

该研究证明JIA-SFMC中IL-17A特征的强度是由多种淋巴样细胞类型决定的,其中包括NCR-ILC3、IL-17A+CD4+、IL-17A+CD8+和IL-17A+γδT细胞。

Blood:巨噬细胞TNF-α纵容供体T细胞合成IFN-γ促进骨髓衰竭

中心点:宿主巨噬细胞来源的TNF-α和供体T细胞上表达的TNF-αR在小鼠免疫介导的骨髓(BM)衰竭的病理机制中发挥重要作用。再生障碍性贫血(AA)患者BM中合成TNF-α的CD16+CD68+巨噬细胞的量要高于健康供体的。摘要:一直以来都认为干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)参与再生障碍性贫血和其他骨髓衰竭综合征的免疫病理生理,但具体机制尚未完全明确。近期,有研究人员在小鼠

Ann Rheum Dis:狼疮抗原中T细胞表位的性质和HLA-DR决定了自身抗体的启动和多样性

狼疮相关自身抗原的独特抗原结构为作为靶标和T、B细胞表位扩散、自身抗体独特类型的多样化提供了基础。

Blood:双功能的PD-1xαCD33xαCD33融合蛋白可逆转急性髓系白血病的适应性免疫逃逸

靶向CD33的双特异性T细胞衔接器(BiTER)AMG330,在体外和小鼠模型中均被证明可高效调节急性髓系白血病(AML)细胞的细胞溶解。但T细胞激活与PD-L1和AML细胞上的其他抑制检查点上调相关,而PD-L1和抑制检查点上调又会导致适应性免疫耐受。PD1和PD-L1阻滞剂或许可中和T细胞功能障碍,但是,这会导致广泛的免疫相关的副反应(irAEs)。Monika Herrmann等人开发出一种

Baidu
map
Baidu
map
Baidu
map